Wai Yuen Tong Medicine Holdings Limited

SEHK:897 Stock Report

Market Cap: HK$238.5m

Wai Yuen Tong Medicine Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Wai Yuen Tong Medicine Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth11.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Low P/S No Reason For Excitement

Nov 19
Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Low P/S No Reason For Excitement

Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too

Jul 26
Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too

Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding

Mar 11
Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding

The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business

Dec 28
The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business

Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Jul 11
Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt

Jul 05
Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt

Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Mar 08
Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now

Aug 18
Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now

Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Mar 17
Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares

Jan 22
Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares

Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Dec 16
Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wai Yuen Tong Medicine Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:897 - Analysts future estimates and past financials data (HKD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20247622N/AN/AN/A
6/30/2024773-12N/AN/AN/A
3/31/2024784-27157192N/A
9/30/20231,35936173233N/A
6/30/20231,3238153199N/A
3/31/2023724-16135168N/A
12/31/20221,314-98149182N/A
9/30/20221,341-176165199N/A
6/30/20221,366-143154184N/A
3/31/20221,391-109143169N/A
12/31/20211,323-122142182N/A
9/30/20211,255-135141194N/A
6/30/20211,182-255247303N/A
3/31/20211,109-376353413N/A
12/31/2020979-98282321N/A
9/30/2020849179211229N/A
6/30/20207353098698N/A
3/31/2020621439-39-33N/A
12/31/2019655253-65-54N/A
9/30/201968966-91-76N/A
6/30/201972071-68-51N/A
3/31/201975175-44-27N/A
12/31/201877920-86-52N/A
9/30/2018807-35-128-77N/A
6/30/2018826-75N/A-77N/A
3/31/2018846-116N/A-77N/A
12/31/2017808-106N/A-61N/A
9/30/2017770-96N/A-46N/A
6/30/2017754-94N/A-68N/A
3/31/2017738-93N/A-90N/A
12/31/2016769-87N/A-65N/A
9/30/2016799-81N/A-41N/A
6/30/2016812-28N/A-78N/A
3/31/201682525N/A-116N/A
9/30/2015827177N/A-93N/A
6/30/2015829149N/A-18N/A
3/31/2015831121N/A58N/A
9/30/2014835120N/A39N/A
6/30/2014850144N/A27N/A
3/31/2014865168N/A15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 897's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 897's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 897's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 897's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 897's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 897's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:02
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Wai Yuen Tong Medicine Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution